Drug Trial Radar · NCT07210554
Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 11, 2025
Primary completion
Mar 27, 2028
Study completion May 8, 2028
Sponsor
- Lead sponsor
- Chengdu Kangnuoxing Biopharma,Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.
Conditions
- Bullous Pemphigoid (BP)
Interventions
Stapokibart injectionBiological
subcutaneous injection
PlaceboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects achieving sustained complete remission (CR) at W36Time frame: Up to 36 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.